Safety and Efficacy Study of rEV131 in Allergic Rhinitis
Status:
Unknown status
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether rEV131 when given as a nasal spray in a single
dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay
fever) caused by an allergen challenge. All patients enrolled will be known to be allergic to
ragweed pollen and will be given ragweed pollen extract in both nostrils 30 minutes after
either rEV131 or innactive vehicle (placebo). The signs and symptoms (sneezing, itching,
stuffiness and runny nose) will each be given a score from 0 to 3 by the patient and these
will be added together and the combined scores from patients treated with rEV131 will be
compared with those who received placebo.